These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1234 related articles for article (PubMed ID: 10228190)

  • 1. Infliximab for the treatment of fistulas in patients with Crohn's disease.
    Present DH; Rutgeerts P; Targan S; Hanauer SB; Mayer L; van Hogezand RA; Podolsky DK; Sands BE; Braakman T; DeWoody KL; Schaible TF; van Deventer SJ
    N Engl J Med; 1999 May; 340(18):1398-405. PubMed ID: 10228190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
    Targan SR; Hanauer SB; van Deventer SJ; Mayer L; Present DH; Braakman T; DeWoody KL; Schaible TF; Rutgeerts PJ
    N Engl J Med; 1997 Oct; 337(15):1029-35. PubMed ID: 9321530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
    Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab maintenance therapy for fistulizing Crohn's disease.
    Sands BE; Anderson FH; Bernstein CN; Chey WY; Feagan BG; Fedorak RN; Kamm MA; Korzenik JR; Lashner BA; Onken JE; Rachmilewitz D; Rutgeerts P; Wild G; Wolf DC; Marsters PA; Travers SB; Blank MA; van Deventer SJ
    N Engl J Med; 2004 Feb; 350(9):876-85. PubMed ID: 14985485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab for active Crohn's disease.
    Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S;
    N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type of fistula determines response to infliximab in patients with fistulous Crohn's disease.
    Parsi MA; Lashner BA; Achkar JP; Connor JT; Brzezinski A
    Am J Gastroenterol; 2004 Mar; 99(3):445-9. PubMed ID: 15056083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease.
    Ochsenkühn T; Göke B; Sackmann M
    Am J Gastroenterol; 2002 Aug; 97(8):2022-5. PubMed ID: 12190171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment with chimeric monoclonal antitumor necrosis factor (infliximab) of patients with active steroid-dependent/resistant Crohn's disease and fistulas].
    Martorana G; Casà A; Oliva L; Orlando A; Cottone M
    Recenti Prog Med; 2001; 92(7-8):451-5. PubMed ID: 11475786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-interleukin-12 antibody for active Crohn's disease.
    Mannon PJ; Fuss IJ; Mayer L; Elson CO; Sandborn WJ; Present D; Dolin B; Goodman N; Groden C; Hornung RL; Quezado M; Yang Z; Neurath MF; Salfeld J; Veldman GM; Schwertschlag U; Strober W;
    N Engl J Med; 2004 Nov; 351(20):2069-79. PubMed ID: 15537905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study.
    Sands BE; Blank MA; Diamond RH; Barrett JP; Van Deventer SJ
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1127-36. PubMed ID: 16611273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn's disease: a preliminary report.
    van der Hagen SJ; Baeten CG; Soeters PB; Russel MG; Beets-Tan RG; van Gemert WG
    Dis Colon Rectum; 2005 Apr; 48(4):758-67. PubMed ID: 15750797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas?
    Gaertner WB; Decanini A; Mellgren A; Lowry AC; Goldberg SM; Madoff RD; Spencer MP
    Dis Colon Rectum; 2007 Nov; 50(11):1754-60. PubMed ID: 17899271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sargramostim for active Crohn's disease.
    Korzenik JR; Dieckgraefe BK; Valentine JF; Hausman DF; Gilbert MJ;
    N Engl J Med; 2005 May; 352(21):2193-201. PubMed ID: 15917384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn's disease in patients treated with infliximab.
    Bouguen G; Trouilloud I; Siproudhis L; Oussalah A; Bigard MA; Bretagne JF; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2009 Oct; 30(7):749-56. PubMed ID: 19583709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
    Sandborn WJ; Hanauer SB
    Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
    Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
    N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab in the surgical management of complex fistulating anal Crohn's disease.
    Talbot C; Sagar PM; Johnston MJ; Finan PJ; Burke D
    Colorectal Dis; 2005 Mar; 7(2):164-8. PubMed ID: 15720356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome of Crohn's disease treated with infliximab.
    Arslan S; Kav T; Besisik F; Kaymakoglu S; Pinarbasi B; Tözün N; Hamzaoglu HO; Duman D; Ulker A; Parlak E; Palabiyikoglu M; Dökmeci A
    Hepatogastroenterology; 2003; 50(52):952-6. PubMed ID: 12845957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
    Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
    Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.